Compare NTAP & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | RVMD |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 19.2B |
| IPO Year | 1996 | N/A |
| Metric | NTAP | RVMD |
|---|---|---|
| Price | $98.59 | $147.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 18 |
| Target Price | $118.25 | ★ $128.11 |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 22.46 | N/A |
| EPS | ★ 4.32 | N/A |
| Revenue | ★ $6,233,200,000.00 | N/A |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $4.91 | $411.49 |
| P/E Ratio | $22.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $80.22 | $34.00 |
| 52 Week High | $126.66 | $136.80 |
| Indicator | NTAP | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.62 | 86.50 |
| Support Level | $95.33 | $93.39 |
| Resistance Level | $108.46 | N/A |
| Average True Range (ATR) | 3.04 | 4.43 |
| MACD | -0.49 | 4.88 |
| Stochastic Oscillator | 31.08 | 98.09 |
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of the cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services. Geographically, the company generates the majority of its revenue from the United States, Canada and Latin America (Americas).
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.